Incyte says EU approves oral treatment for chronic skin disease
INCY•The European Commission approved Incyte’s once-daily oral treatment Povofortay for adults with moderate-to-severe hidradenitis suppurativa who have not responded adequately to, or cannot take, anti-tumor necrosis factor therapies.




